Zoster vaccine recombinant, adjuvanted(GlaxoSmithKline Plc)

5月9日，葛兰素史克大中华和洲际区域高级副总裁Mike Crichton官宣重大人事任命：任命余慧明(Sherman Yu)为副总裁兼中国总经理，自2024年7月1日起生效。现任GSK 副总裁、中国总经理Cecilia Qi(齐欣)被任命为大中华和洲际区域(GCI)副总裁兼疫苗业务负责人。两人将于6月1日起进行正式交接，并于7月1日各自履新。中国市场一直是GSK集团及GCI区域的战略重点。Cecilia在过去四年半担任中国总经理期间，为中国市场的发展制定了清晰的战略规划，并围绕实现这一目标组建了一支高效杰出的团队。她带领中国团队经历了新冠疫情期间最具挑战的时刻，同时秉持着对中国组织和员工始终如一的承诺以及心系患者的初心，与全球和区域的管理团队紧密合作，成功推出了一系列战略转型举措，确保GSK在中国市场实现高速成长。在她的领导下，中国团队成功获批并上市了21款新产品及新适应症，其中包括欣安立适、新可来和倍力腾，中国区的业绩增长自2021年以来保持数倍领先于市场平均增速。Cecilia的此次任命恰逢其时，有利于进一步推动疫苗业务在GCI区域的发展，促进欣安立适进一步增长，加速Arexvy疫苗的审批和市场渗透。资料显示，齐欣毕业于上海交通大学医学院，曾在施贵宝、辉瑞、赛诺菲、默沙东多家外企任职。2004 年，她加入GSK中国担任疫苗业务市场总监，此后历任肝炎业务部总经理、数字营销和商业卓越团队负责人。2017年，齐欣被任命为 GSK 中国香港和澳门地区总经理，2019年晋升为副总裁及中国区疫苗总经理。齐欣（Cecilia Qi）余慧明也是医药领域的资深人士。在职业生涯的早期，她曾先后在惠氏和辉瑞疫苗担任业务管理和市场营销职务。2012年，余慧明加入山德士担任香港地区总经理后又同时负责山德士港台地区业务；2019年5月被任命为山德士大中华区首席运营官。2022年初，余慧明就任山德士大中华区总裁职务，同年9月离任。往期推荐视角 | 纸面之外的药明康德2023年报Claudin18.2ADC赛道群雄逐鹿：3家率先进入III期临床下一个10亿美元重磅炸弹选手"裁员潮”仍在加剧：2月多家药企裁员点击下方“药研网”，关注更多精彩内容

In a significant development for GSK China, the pharmaceutical giant has undergone a leadership transition, marking the start of a new era. According to reports, Cecilia Qi, the current Vice President and General Manager of GSK China, has been appointed as the Vice President and Head of Vaccines for GSK Greater China and Intercontinental Region. Meanwhile, Sherman Yu, the Vice President and General Manager of GSK Taiwan, will assume the role of Vice President and General Manager of GSK China. This transition is set to take effect on June 1, with both executives assuming their new positions on July 1. Cecilia Qi's Achievements and Background: Cecilia Qi, a graduate of Shanghai Jiao Tong University School of Medicine, has a wealth of experience in the pharmaceutical industry. She has held various positions in multinational companies such as Shiseido, Pfizer, Sanofi, and Merck. Qi joined GSK China in 2004 as the Market Director for the Vaccine Business. Over the years, she has taken on roles such as General Manager of the Hepatitis Business Unit and Head of Digital Marketing and Commercial Excellence. In 2017, she was appointed as the General Manager for GSK Hong Kong and Macau and later promoted to Vice President and General Manager of GSK China's Vaccine Business. With her leadership, GSK China has achieved significant milestones, including the approval and launch of 21 new products and indications, while maintaining consistent growth. Sherman Yu's Professional Background: Sherman Yu is a seasoned professional in the pharmaceutical field. Earlier in her career, she held positions in business management and marketing at Wyeth and Pfizer Vaccines. In 2012, Yu joined GSK as the General Manager for Hong Kong and subsequently took on additional responsibilities for GSK's business in Taiwan. In May 2019, she was appointed as the Chief Operating Officer for GSK Greater China. Under Yu's leadership, GSK Taiwan achieved remarkable performance growth, particularly in the vaccine business, including successful market launches of vaccines such as Shingrix and accelerated approvals for Arexvy. GSK's Strategic Focus on the Chinese Market: The Chinese market has always been a strategic focus for GSK. In January of this year, the company reorganized its operations in China, establishing three core business units: Specialty Care, Vaccines, and Respiratory. The newly appointed leadership team is committed to positioning GSK China among the top ten multinational pharmaceutical companies in China by 2030. Financial Performance and Growth: GSK's first-quarter financial report, released on May 1, showcased promising results. The company generated total revenue of £7.367 billion, with a year-on-year growth of 10%. Excluding the impact of COVID-19-related products, the revenue growth stood at 13%. Notably, the vaccine business emerged as a key driver of growth, with sales of RSV vaccine Arexvy reaching £182 million, representing a 22% increase, and sales of shingles vaccine Arexvy reaching £945 million, reflecting an 18% increase. With the appointment of Cecilia Qi as the Vice President and Head of Vaccines for GSK Greater China and Intercontinental Region, and Sherman Yu as the Vice President and General Manager of GSK China, GSK is poised for a new chapter in its journey in China. Their collective expertise and strategic vision are expected to drive further growth and solidify GSK's position as a leader in the Chinese pharmaceutical market. As GSK embraces this leadership transition, it prepares to continue its commitment to innovation, healthcare advancement, and improving the lives of patients in China and beyond.